Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1184 Results

Intervention Indication Therapeutic Area Year Actions
Asciminib for chronic myeloid leukaemia – chronic phase -third line Asciminib (ABL001) Chronic myeloid leukaemia (CML) Haematological Cancer and Lymphomas 2020 View  |  Download
Arimoclomol for Niemann-Pick Disease type C - add-on therapy Arimoclomol (BRX-345) Niemann-Pick Disease Endocrine Nutritional and Metabolic Disorders , Genetic Disorders , Neurology 2017 View  |  Download
AR101 peanut allergy immunotherapy for adult and paediatric patients Palforzia (AR101) Peanut allergy Immunology 2017 View  |  Download
AR101 for peanut allergy in children aged 1 – 3 years Palforzia (AR101) Peanut allergy Immunology 2022 View  |  Download
Aprocitentan for treating resistant hypertension Aprocitentan (ACT-132577; AC-080; ACT 13257; Actelion) Resistant hypertension Cardiovascular System 2023 View  |  Download
Apremilast for treating moderate to severe plaque psoriasis in children and young people Apremilast (Otezla; CC-10004) Plaque psoriasis Dermatology 2023 View  |  Download
Apremilast for oral ulcers in active Beh cet’s disease Apremilast (Otezla; CC-10004) Oral ulcers Dental and Oral Health 2018 View  |  Download
Apalutamide with primary radiation therapy for treating high-risk, localised or locally advanced prostate cancer Apalutamide (Erleada; ARN-509) , Primary radiation therapy Prostate cancer Male Reproductive Cancer 2022 View  |  Download
Apalutamide in addition to androgen deprivation therapy for metastatic hormone-sensitive prostate cancer Apalutamide (Erleada; ARN-509) Prostate cancer Male Reproductive Cancer 2018 View  |  Download
Apalutamide in Addition to Abiraterone and Prednisone/Prednisolone for Metastatic Castration-resistant Prostate Cancer – First Line Abiraterone acetate (Zytiga; Yonsa) , Apalutamide (Erleada; ARN-509) , Prednisone (Decadron; Lodotra) Prostate cancer Male Reproductive Cancer 2018 View  |  Download
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications